These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 33293006)

  • 21. Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19.
    Peña-Silva R; Duffull SB; Steer AC; Jaramillo-Rincon SX; Gwee A; Zhu X
    Br J Clin Pharmacol; 2021 Mar; 87(3):1589-1590. PubMed ID: 32779815
    [No Abstract]   [Full Text] [Related]  

  • 22. Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2.
    Jeffreys LN; Pennington SH; Duggan J; Caygill CH; Lopeman RC; Breen AF; Jinks JB; Ardrey A; Donnellan S; Patterson EI; Hughes GL; Hong DW; O'Neill PM; Aljayyoussi G; Owen A; Ward SA; Biagini GA
    Int J Antimicrob Agents; 2022 Mar; 59(3):106542. PubMed ID: 35093538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ivermectin as a possible treatment for COVID-19: a review of the 2022 protocols.
    Marques LLM; Beneti SC; Pinzon C; Cardoso FAR
    Braz J Biol; 2022; 84():e258325. PubMed ID: 35584459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Could the COVID-19-Driven Increased Use of Ivermectin Lead to Incidents of Imbalanced Gut Microbiota and Dysbiosis?
    Dicks LMT; Deane SM; Grobbelaar MJ
    Probiotics Antimicrob Proteins; 2022 Apr; 14(2):217-223. PubMed ID: 35218001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes.
    Kaur H; Shekhar N; Sharma S; Sarma P; Prakash A; Medhi B
    Pharmacol Rep; 2021 Jun; 73(3):736-749. PubMed ID: 33389725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Letter in reply: more power to ivermectin multidrug therapy.
    Hazan S; Dave S; Borody TJ; McCullough PA
    Future Microbiol; 2022 Nov; 17():1283-1285. PubMed ID: 36134721
    [No Abstract]   [Full Text] [Related]  

  • 27. Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients.
    Okumuş N; Demirtürk N; Çetinkaya RA; Güner R; Avcı İY; Orhan S; Konya P; Şaylan B; Karalezli A; Yamanel L; Kayaaslan B; Yılmaz G; Savaşçı Ü; Eser F; Taşkın G
    BMC Infect Dis; 2021 May; 21(1):411. PubMed ID: 33947344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Caution should be exercised when assessing ivermectin for the treatment of COVID-19 in systematic reviews.
    Deng J; Zhou F; Heybati K; Kavanagh K
    Rev Med Virol; 2022 Sep; 32(5):e2317. PubMed ID: 34888992
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy of single-dose and double-dose ivermectin early treatment in preventing progression to hospitalization in mild COVID-19: A multi-arm, parallel-group randomized, double-blind, placebo-controlled trial.
    Mirahmadizadeh A; Semati A; Heiran A; Ebrahimi M; Hemmati A; Karimi M; Basir S; Zare M; Charlys da Costa A; Zeinali M; Sargolzaee M; Eilami O
    Respirology; 2022 Sep; 27(9):758-766. PubMed ID: 35738778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unethical studies of ivermectin for covid-19.
    Meyerowitz-Katz G; Wieten S; Medina Arellano MJ; Yamey G
    BMJ; 2022 Apr; 377():o917. PubMed ID: 35422425
    [No Abstract]   [Full Text] [Related]  

  • 31. Pandemic and promise: progress towards finding an effective treatment for Novel Coronavirus 19.
    Merone L; Finlay S
    Aust N Z J Public Health; 2020 Dec; 44(6):437-439. PubMed ID: 33044799
    [No Abstract]   [Full Text] [Related]  

  • 32. COVID-19 in Still's disease.
    de Carvalho JF
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12627-12629. PubMed ID: 33378008
    [No Abstract]   [Full Text] [Related]  

  • 33. Considerations on the Article "Antiviral and Anti-Inflammatory Properties of Ivermectin and its Potential Use in COVID-19".
    Hernández-Vásquez A; Vargas-Fernández R; Azañedo D
    Arch Bronconeumol (Engl Ed); 2020 Dec; 56(12):832. PubMed ID: 33051096
    [No Abstract]   [Full Text] [Related]  

  • 34. Ivermectin in COVID-19: What do we know?
    Pandey S; Pathak SK; Pandey A; Salunke AA; Chawla J; Sharma A; Sharma S; Thivari P; Ratna HVK
    Diabetes Metab Syndr; 2020; 14(6):1921-1922. PubMed ID: 33032231
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment of COVID-19: a review of current and prospective pharmacotherapies.
    Quek E; Tahir H; Kumar P; Hastings R; Jha R
    Br J Hosp Med (Lond); 2021 Mar; 82(3):1-9. PubMed ID: 33792391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ivermectin in COVID-19 Management: What is the Current Evidence?
    Eerike M; Raj GM; Priyadarshini R; Ravi G; Bisoi D; Konda VGR
    Infect Disord Drug Targets; 2022; 22(4):e190122200367. PubMed ID: 35043770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness.
    Ahmed S; Karim MM; Ross AG; Hossain MS; Clemens JD; Sumiya MK; Phru CS; Rahman M; Zaman K; Somani J; Yasmin R; Hasnat MA; Kabir A; Aziz AB; Khan WA
    Int J Infect Dis; 2021 Feb; 103():214-216. PubMed ID: 33278625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
    Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Achinelli F; Guglielmone HA; Ojeda J; Medina F; Farizano Salazar D; Andino G; Ruiz Diaz NE; Kawerin P; Meza E; Dellamea S; Aquino A; Flores V; Martemucci CN; Vernengo MM; Martinez SM; Segovia JE; Aguirre MG
    Trials; 2020 Nov; 21(1):965. PubMed ID: 33234158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis.
    Padhy BM; Mohanty RR; Das S; Meher BR
    J Pharm Pharm Sci; 2020; 23():462-469. PubMed ID: 33227231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving Ivermectin for the treatment of COVID-19.
    Kow CS; Hasan SS
    Am J Ther; 2021 Aug; 28(5):e616-e619. PubMed ID: 34387564
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.